

CONTRACT UPDATES

SERVICE AGREEMENTS

PRODUCT AGREEMENTS

AMGEN[®]

New Amgen Agreement!

Oncology Associates and Amgen are pleased to announce a *new and simplified* Amgen Portfolio Contract (APC) for 2004. **The contract term began March 1, 2004 and extends to 2006.**

Highlights from APC include:

- > 6 month special – 10% off-invoice for Aranesp[®]
- > Same great off-invoice discounts on Neupogen[®] and Neulasta[®] as 2003
- > Superior rebates on both Aranesp[®] and Neulasta[®] compared to 2003 Amgen contracts
- > Rebates will be paid quarterly

Please contact your Amgen Sales Representative to find out how you can begin earning these quarterly rebates. For more information, contact Oncology Associates at **888-732-7352**.

Product	Description	NDC#
Aranesp (darbepoetin alfa) prefilled syringe or vial	25 mcg, 1.0 ml	55513-010-04
	40 mcg, 1.0 ml	55513-011-04
	60 mcg, 1.0 ml	55513-012-01
	100 mcg, 1.0 ml	55513-013-04
	150 mcg, .075 ml	55513-054-04
Neulasta (pegfilgrastim)	200 mcg, 1.0 ml	55513-014-01
	300 mcg, 1.0 ml	55513-015-01
	6 mg/0.6 ml	55513-190-01
Neupogen (filgrastim) pre-filled syringe)	300 mcg/0.5 ml	55513-0924-01
	480 mcg/0.8 ml	55513-0209-01
Neupogen (filgrastim) pre-filled vial	300 mcg/1.0 ml	55513-0530-01
	480 mcg/1.6 ml	55513-0546-01



Agreement Reminder for Kytril[®]

Oncology Associates reminds you of its new agreement with Roche for Kytril[®] (granisetron hydrochloride). This members' product contract includes 1mL single dose vials and 4 mL multi dose vials of Kytril[®].

This exciting agreement offers a rebate as well as additional enhancements of a new super tier pricing level for those who qualify. The terms of the new contract became effective **January 1, 2004**.

Contact your Roche Oncology Specialist to learn all of the details regarding this new agreement.

Kytril[®] Injection is available as follows:

NDC	Package Size	Strength
00004-0239-09	1mg/mL	
	1mL Single Dose Vial	1mg/mL
00004-0240-09	1 mg/mL	
	4 mL Multi Dose Vial	1mg/mL



Contract Reminder

Oncology Associates would like to remind you of its contract for Innohep[®] (tinzaparin sodium for injection) with Pharmion Corporation. Innohep[®] is a once-daily low molecular weight heparin for the treatment of acute symptomatic deep vein thrombosis (DVT) with or without pulmonary embolism when administered in conjunction with warfarin sodium (such as Coumadin[®]).

Innohep[®] is currently available through FloridaInfusion Services. Contact FIS directly at 800-624-0152 to place an order.

NDC#	Product Name	Strength	Package Size
67211-342-08	Innohep [®]	20,000 IU/mL	2mL vial
67211-342-53	Innohep [®]	20,000 IU/mL	10x2mL vial